Bicara Therapeutics (BCAX) Amortizatization of Intangibles (2024 - 2026)
Bicara Therapeutics (BCAX) reported Amortizatization of Intangibles of -$338000.0 for Q1 2026, down 344.93% on a YoY basis from $138000.0 in Q1 2025, and down 25.65% quarter-over-quarter from -$269000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Bicara Therapeutics has reported Amortizatization of Intangibles for 3 years, with the latest figure at -$338000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 344.93% year-over-year to -$338000.0; the trailing twelve-month figure through Mar 2026 stood at -$777000.0 (down 1164.38% YoY), and the FY2025 full-year result was -$301000.0, changed N/A from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at -$338000.0, down from -$269000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $211000.0 in Q2 2025, with the low at -$381000.0 in Q3 2025.
- Historically, Amortizatization of Intangibles has averaged -$71000.0 across 3 years, with a median of $65000.0 in 2024.
- The largest YoY upside for Amortizatization of Intangibles was 219.7% in 2025 against a maximum downside of 660.29% in 2025.
- Bicara Therapeutics' Amortizatization of Intangibles stood at -$199000.0 in 2024, then tumbled by 35.18% to -$269000.0 in 2025, then dropped by 25.65% to -$338000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$338000.0 (Q1 2026), -$269000.0 (Q4 2025), and -$381000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Bicara Therapeutics | 1.31 Bn | 1.31 Bn | - | -338,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -338,000.00 |
| Mar 31, 2026 | -338,000.00 |
| Dec 31, 2025 | -269,000.00 |
| Dec 31, 2025 | -269,000.00 |
| Sep 30, 2025 | -381,000.00 |
| Sep 30, 2025 | -381,000.00 |
| Jun 30, 2025 | 211,000.00 |
| Jun 30, 2025 | 211,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Dec 31, 2024 | -199,000.00 |
| Dec 31, 2024 | -199,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Mar 31, 2024 | 65,000.00 |
| Mar 31, 2024 | 65,000.00 |